Therapeutic peptides and use thereof against huntington's disease

US8987211B2 · kind B2 · utility

Assignees

• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES · FR

Inventors

• Florence Maschat · Boisseron, FR
• Marie-Laure Parmentier · Montpellier, FR
• Nathalie Bonneaud · Montpellier, FR
• Yoan Arribat · Montpellier, FR

Key dates

• Filing date: Apr 12, 2012
• Grant date: Mar 24, 2015
• Expiry date: Apr 12, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/60
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Fusion proteins that contain the fusion of (i) a peptide of less than 100 amino acids comprising a first amino acid sequence comprising AASSG (SEQ ID NO: 1) and a second amino acid sequence comprising XAGXDXXTEXPXS (SEQ ID NO: 2), wherein X designates any amino acid, and (ii) a protein transduction domain (PTD) are provided, along with pharmaceutical compositions containing the fusion protein. The proteins can be used to treat Huntington's disease.